Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Insider Monkey on MSN7d
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Fintel on MSN8d
Leerink Partners Upgrades Genmab A (GMAB)
Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...
Genmab A/S (NASDAQ:GMAB) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...
Morningstar2d
Genmab AS ADR GMAB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q3 Earnings Forecast for Genmab A/S Issued By William Blair
Equities researchers at William Blair issued their Q3 2025 earnings per share estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps forecasts ...